A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs LGD 6972 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Ligand Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 According to a Ligand Pharmaceuticals media release, this trial is recently completed.
    • 14 Nov 2017 Status changed from active, no longer recruiting to completed, according to a Ligand Pharmaceuticals media release.
    • 05 Sep 2017 According to a Ligand Pharmaceuticals media release, the company plans to present detailed study results, including data from the secondary efficacy and safety endpoints, at upcoming medical meetings and in a peer-reviewed publication.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top